Picard Medical, Inc. announced that its CEO will present data on the fully implantable Emperor Total Artificial Heart at the upcoming CSI Focus D-HF 2025 conference in Frankfurt, Germany.
The conference focuses on device-based therapies for heart failure and brings together leading experts in the field.
SynCardia Systems LLC, a subsidiary of Picard Medical, is a leader in total artificial heart technology with over 2,100 implants across 27 countries.
Total Artificial Heart Technology
SynCardia Systems LLC offers the only commercially available total artificial heart technology approved by the FDA and Health Canada.
Conference Participation
Picard Medical CEO will present data at the CSI Focus D-HF 2025 conference, a key event in the field of heart failure device therapies.
Global Impact
SynCardia's Total Artificial Heart has been implanted in over 2,100 patients worldwide, making it a widely used technology in heart failure treatment.
- The presentation at CSI Focus D-HF 2025 will showcase the advancements in total artificial heart technology by Picard Medical and SynCardia Systems LLC.
- The company's participation in the conference reflects its commitment to innovation and collaboration in the field of heart failure treatments.
Picard Medical's presence at the CSI Focus D-HF 2025 conference signifies a significant step towards advancing heart failure device therapies and highlighting the innovative solutions offered by SynCardia Systems LLC.